Alternative Names: Cardiac Insufficiency
Congestive heart failure (CHF) is a serious condition in which the heart is not pumping well enough to meet the body's demand for oxygen. This condition has its name due to the heart failing to pump efficiently, which often results in congestion of the lungs. As a result, the heart tries to overcompensate for the problem, which only makes the problem worse.
Due to weakened heart muscles, blood supply to the kidneys may be reduced, which in turn impairs their ability to excrete salt and water. As a result the body retains more fluid, some of which may accumulate in the extremities, resulting in edema of the ankles and/or feet.
The weakened heart muscles may not be able to supply enough blood to the kidneys, which then begin to lose their normal ability to excrete salt (sodium) and water. This diminished kidney function can cause the body to retain more fluid.
Congestive heart failure leads to reduced blood supply to the kidneys, which leads in turn reduced kidney function, and in turn excess fluid retention (edema). The lungs may become congested with fluid (pulmonary edema) and thus the ability to exercise is decreased.
Renal insufficiency due to underperfusion from a failing heart is more widespread than commonly thought.
Congestive heart failure occurs in about 7% of symptomatic patients with hemochromatosis. If untreated, patients may develop an acute onset of severe congestive heart failure with rapid progression to death.
A study found that elderly people who drank at least 1.5 drinks per day had a risk of heart failure 47% lower than abstainers, regardless of age, race, blood pressure, history of diabetes, smoking and other factors.
Studies do not justify advising lifelong nondrinkers to start drinking for health, especially because most have good reasons for abstaining. People with liver disease or a history of alcohol abuse should not drink at all, while those with diabetes and hypertension may partake in light alcohol consumption.
In a sample of 1,011 patients with stage II cardiac insufficiency, a standardized hawthorn extract containing 84mg of oligomeric procyanidins improved ejection fraction and resting pulse rate, and produced a reduction in cardiac arrhythmias. Duration of the study was 24 weeks. [Eur J Heart Fail 2000;2(4): pp.431-7]
Clinical trials with an extract (WS 1442) have successfully demonstrated improved cardiac function and improved quality of life primarily in patients with early stage CHF. For the treatment of early stage CHF, the effective daily dosage of WS 1442 (standardized to 18.75% oligomeric procyanidins) has ranged from 160-900mg per day, divided into 2-3 doses. Benefit has been shown in the 160-480mg per day range. [Fortschr Med 1996;114: pp.291-6]
Whole fruit and fruit and vegetable juice, both high in potassium, are recommended by some doctors for congestive heart failure (CHF). This dietary change should, however, be discussed with a healthcare provider because several drugs given to people with CHF can actually cause retention of potassium, making dietary potassium, even from fruit, dangerous. Bananas are a rich source of potassium and need to be avoided in persons taking potassium-sparing diuretics.
Potassium-sparing diuretics such as Aldactone or Dyrenium help the body to retain potassium and are often used in congestive heart failure patients, often along with the other two types of diuretics. They do not significantly lower blood pressure.
Loop diuretics such as Lasix or Bumex are often used to counter congestive heart failure symptoms and are especially useful in emergencies. They do not, however, significantly lower blood pressure. Thiazide diuretics, such as Esidrix or Zaroxolyn, can be used to treat edema in heart failure.
CoQ10 is known to be highly concentrated in heart muscle cells due to the high energy requirements of this cell type. The great bulk of clinical work with CoQ10 has focused on heart disease. Specifically, congestive heart failure (from a wide variety of causes) has been strongly correlated with significantly low blood and tissue levels of CoQ10 [Proc. Natl. Acad. Sci., U.S.A., vol. 82(3), pp. 901-4].
The severity of heart failure correlates with the severity of CoQ10 deficiency [Drugs Exptl. Clin. Res. X(7) pp.497-502]. This CoQ10 deficiency may well be a primary causative factor in some types of heart muscle dysfunction while in others it may be a secondary phenomenon. Whether primary, secondary or both, this deficiency of CoQ10 appears to be a major treatable factor in the otherwise inexorable progression of heart failure.
The efficacy and safety of CoQ10 in the treatment of congestive heart failure, whether related to primary cardiomyopathies or secondary forms of heart failure, appears to be well-established.